Logo
x

Search category

Subscribe Now

Biosimilars

13th Summit on Biosimilars & Innovator Biologics

13th Summit on Biosimilars & Innovator Biologics

  • May 23, 2022
Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

  • October 27, 2021
Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar...

  • October 18, 2021
Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countries

Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar- ustekinumab in Russia and other CIS Countr...

  • October 18, 2021
Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

Gan & Lee Completes P-III Studies of GL-GLA for Patients with T1D & T2D

  • October 15, 2021
Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related M...

  • October 5, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.